Publication:
Estrogen Receptor Positive/Progesterone Receptor Negative Breast Carcinomas: A Subgroup Deserves Particular Interest

Loading...
Thumbnail Image

Date

2015-08-01

Authors

Gucin, ZÜHAL
GECER, Melin Ozgun
Buyukpinarbasili, NUR
SONMEZ, Cavide
Ersoy, YELİZ EMİNE
MUSLUMANOGLU, Mahmut

Journal Title

Journal ISSN

Volume Title

Publisher

Research Projects

Organizational Units

Journal Issue

Metrics

Search on Google Scholar

Abstract

Objective: Breast carcinomas positive for the estrogen receptor (ER+) but negative for the progesterone receptor (PR−) have unfavorable prognostic features and are resistant to tamoxifen therapy. The goal of this study was to highlight the significance of PR− breast carcinomas. Methods: Therefore, 146 breast carcinomas comprising 87 ER+/PR+ and 59 ER+/PR− carcinomas were examined. These two groups were compared in terms of age; tumor type; tumor size; histologic grade; presence of an in situ component; lymphovascular and perineural invasion; and ER, PR, c-Erb B2, Ki-67, and epidermal growth factor receptor (EGFR) status. Results: While the number of metastatic lymph node and related pN2+pN3 tumors were found to be significantly higher in the ER+/ PR− group, the differences with respect to the tumor size, metastatic lymph node size, and frequency of lymphovascular invasion were nearly significant. Conclusion: ER+/PR− tumors have an unfavorable prognosis and show a clinical behavior closer to triple negative ones, although classified as luminal tumors. Revealing the mechanisms causing these differences will enhance the success of breast cancer therapy.

Description

Keywords

Breast carcinoma, estrogen receptor, progesterone receptor, luminal type, prognosis

Citation

Gucin Z., GECER M. O. , Buyukpinarbasili N., SONMEZ C., Ersoy Y. E. , MUSLUMANOGLU M., -Estrogen Receptor Positive/Progesterone Receptor Negative Breast Carcinomas: A Subgroup Deserves Particular Interest-, BEZMIALEM SCIENCE, cilt.3, ss.29-32, 2015
Page Views

5

File Downloads

9

Sustainable Development Goals